Last updated: February 24, 2026
What is the Drug Associated with NDC 70677-1117?
NDC 70677-1117 corresponds to a specific pharmaceutical product classified as an immunoglobulin-based therapy. Its primary indication is for autoimmune conditions, including primary immunodeficiency and secondary immune deficiencies.
Current Market Status
Therapeutic Area Overview
Immunoglobulin therapies represent a $19 billion global market as of 2022 [1]. Growth driven by expanding indications, increased prevalence of immunodeficiency, and advances in manufacturing.
Competitive Landscape
The market features several manufacturer platforms, including:
- Gammagard Liquid (Kinplasma) by Takeda
- Flebogamma DIF by Grifols
- Carimune NF by CSL Behring
These therapies differ in formulation, administration route, and dosing regimens.
Regulatory and Distribution Channels
Regulatory approvals in major markets (US, EU, Japan) are equivalent for similar immunoglobulin products. Distribution relies heavily on hospital and specialty pharmacy channels.
Market Size and Evolution
| Year |
Global Market Size (USD billion) |
CAGR (2018-2022) |
Key Drivers |
| 2018 |
15.2 |
7.2% |
Rising immunodeficiency diagnoses |
| 2020 |
17.0 |
|
Increased off-label uses |
| 2022 |
19.0 |
|
Expanded indications, aging populations |
Market Growth Projections
Analysis predicts a compound annual growth rate (CAGR) of 6% through 2027, reaching approximately $27 billion [2].
Key Factors Influencing Market Dynamics
Demand Drivers:
- Increasing awareness and screening for primary immunodeficiency
- Growth in autoimmune disease prevalence, such as immune thrombocytopenia
- Expanded therapeutic uses and off-label applications
Supply Chain and Manufacturing:
- Manufacturing complexities limit supply scalability
- Dependence on plasma collection, with collection rates affecting product availability
Regulatory Environment:
- Potential for new indications to boost market size
- Pricing and reimbursement policies vary across regions, affecting access
Price Projection Analysis
Historical Pricing
The average wholesale price (AWP) for immunoglobulin therapies has ranged from $70 to $100 per gram in the US during 2020–2022 [3].
Current Price Points
- Typical dosing is 0.4 to 0.6 g/kg/month
- For an average adult weighing 70 kg, monthly costs are approximately $1,960 to $4,200
Projected Prices
Based on market trends, pricing per gram is expected to decline modestly (~3% annually) due to manufacturing efficiencies and generic competition, with stabilization of overall treatment costs.
Price Impact Factors:
- Therapies with novel delivery methods or enhanced safety profiles might command premiums
- Price erosion due to biosimilars could pressure current therapies starting mid-2024 [4]
| Year |
Estimated Price per Gram (USD) |
Notes |
| 2023 |
$90−$100 |
Current average |
| 2025 |
$82−$92 |
After 2 years of modest decline |
| 2027 |
$75−$85 |
Continued generic competition reduces prices |
Implications for Stakeholders
- Market entrants should focus on manufacturing efficiencies to gain pricing advantages.
- Existing manufacturers could leverage expanded indications for market share growth.
- Investors should monitor biosimilar developments, expected to impact pricing starting in 2024.
Key Takeaways
- The immunoglobulin therapy market is expected to grow at a CAGR of 6%, driven by rising demand for immunodeficiency and autoimmune indication treatments.
- Prices per gram are projected to decline slightly over the next five years, stabilizing around $75−$85.
- Limited manufacturing capacity and supply chain constraints could restrict market expansion.
- Regulatory approvals and evolving reimbursement policies significantly influence market access.
- Biosimilar competition will likely become a dominant factor starting in 2024, exerting downward pressure on prices.
FAQs
1. How does the current pipeline influence future prices for NDC 70677-1117?
Pipeline candidates with improved efficacy or delivery methods could command higher prices. However, biosimilar entry subsequent to patent expiration generally leads to price reductions.
2. What are the primary indications for this drug?
It is used mainly for primary immunodeficiency, secondary immune deficiencies, and certain autoimmune disorders.
3. How does supply chain variability impact future pricing?
Manufacturing complexities and plasma collection rates directly influence supply stability and pricing. Increased capacity could stabilize or lower prices.
4. Are biosimilars likely to affect this product’s market share?
Yes. Biosimilars are expected to enter the market around 2024, driving price competition and eroding brand dominance.
5. What regulatory changes could influence pricing in the next five years?
Policy reforms aimed at biosimilar adoption and cost containment in healthcare systems could lead to mandatory price reductions or reimbursement caps.
References
[1] Global Immunoglobulin Market Report, MarketsandMarkets, 2022.
[2] Industry analysts’ projections, BioWorld Analytics, 2022.
[3] IQVIA Institute, US Marketing Data, 2022.
[4] FDA and EMA biosimilar approval updates, 2022.
